Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer

Annals of Surgical Oncology

Volumn 10, Issue 3, 2003, Pages 234-241

  Garcia I ^a   Vizoso, F ^a   Martin A ^a   Sanz, L ^a   Abdel Lah, O ^a   Raigoso, P ^b   Garcia Muniz J L ^a  

^a HOSPITAL DE JOVE   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Epidermal growth factor receptor; Gastric cancer; HER2; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CELL LEVEL; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN ANALYSIS; RADIOASSAY; STOMACH CANCER; SURVIVAL TIME; ADENOCARCINOMA; BIOSYNTHESIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL;

EID: 0037795412     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.05.010     Document Type: Article

References (54)

1. Ullrich A, Schlessinfer J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
2. Alroy I, Yarden Y. The ErbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEES Lett 1997;410:83-6.
3. Klapper LN, Kirchbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
4. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994;19:459-63.
5. Barnard JA, Beauchamp RD, Russel WE, Dubois RN, Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995;108:564-80.
6. Woodbum JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
7. Moroni M, Willingham M, Beguinot L. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem 1992;267:2712-22.
8. Hirao T, Sawada H, Koyama F, et al. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther 1999;6:423-7.
9. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of neu differentiation factor and epidermal growth factor signalling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
10. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signalling. EMBO J 1997;16:1647-55.
11. De Lange T. Activation of telomerase in a human tumor. Proc Natl Acad Sci U S A 1994;91:2882-5.
12. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41:695-706.
13. Baselga J, Tripathy D, Mendelson J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
14. Baselga J, Norton L, Albanell J, Kim YM, Mendelson J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
16. Salomon DS, Brandt R, Ciardello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
17. Koeppen HKW, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumors: an immunohistochemical survey. Histopathology 2001;38:96-104.
18. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-52.
19. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137-41.
20. Yonemura Y, Sugiyama K, Fujimura T, et al. Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology 1989;46:158-61.
21. Bennet C, Paterson IM, Corbishley CM, Luqmani YA. Expression of growth factor and epidermal growth factor receptor encoded transcripts in human gastric tissues. Cancer Res 1989;49:2104-11.
22. Yoshida K, Tsuda T, Matsumura T, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57:285-90.
23. Houldsworth J, Cordon-Cardo C, Landanyi M, Kelsen DP, Chaganti RSK. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22.
24. Pfeiffer A, Rothbauer E, Wiebeke B, Pratschke E, Kramling HJ, Mann K. Increased epidermal growth factor receptors in gastric carcinomas. Gastroenterology 1990;98:961-7.
25. Iida A, Hirose K, Arai M, Yamaguchi A, Nakagawara G. Relationship among the expression of epidermal growth factor, proliferating cell nuclear antigen labelling index, and lymph node metastasis in gastric cancer. Oncology 1995;52:189-95.
26. Hirono Y, Tsugawa K, Fushida S, et al. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Oncology 1995;52:182-8.
27. Anzai H. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer 1998;34:558-65.
28. Buján MC, Ruibal A, Aza J. Adenocarcinoma gástrico: expresión de la oncoproteína neu/c-erbB-2 receptor del factor de crecimiento epidérmico, catepsina D, receptor de progesterona y glucoproteína asociada a tumores-72 en función del tipo histológico. Rev Esp Enferm Dig 1999;91:826-31.
29. Sanz-Ortega J, Steinberg SM, Moro E, et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-erbB2, c-myc and EGFr as prognosis factors in gastric cancer. Histol Histopathol 2000;15:455-62.
30. García I, Vizoso F, Andicoechea A, et al. Clinical significance of epidermal growth factor receptor content in gastric cancer. Int J Biol Markers 2001;16:183-8.
31. ERBB2 expression and the gene amplification. Cancer Res 1990;50:8002-9.
32. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW. C-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinomas: an immunohistochemical study on archival material. Int J Cancer 1991;48:668-71.
33. Yonemura Y, Ninomiya I, Oyohama S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Cancer 1992;67:2914-8.
34. Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 1993;53:75-9.
35. Lee EY, Cibull ME, Strodel WE, Haley JV. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 1994;118:235-9.
36. Tsugawa K, Yonemura Y, Hirono Y, et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998;55:457-81.
37. Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Mod Pathol 1998;11:870-7.
38. Gürel S, Dolar E, Yerci Ö, et al. The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 1999;27:74-8.
39. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894-902.
40. García I, Vizoso F, Andicoechea A, et al. C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa. Int J Biol Markers 2000;15:231-4.
41. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-9.
42. Koullias GJ, Kouraklis GP, Raftopoulos IS, Davaris PS, Papadopoulos SA, Golematis BC. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J Surg Oncol 1996;63:166-71.
43. Hermaneck P, Sobin LJ, eds. UICC TNM Classification of Malignant Tumors. 4th ed, 2nd rev. Berlin: Springer, 1992.
44. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma - an attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
45. Marchalonis JJ. An enzymatic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969;13:299-305.
46. Formento JE, Francoual M, Formento P, et al. Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1990;17:211-9.
47. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
48. McKenzie SJ, Marks PJ, Lam T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989;4:543-8.
49. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;52:457-81.
50. Mantel N, Myers M. Problems of convergence of maximum likelihood iterative procedures in multiparameter situations. J Am Stat Assoc 1971;66:484-91.
51. Tandon AK, Clark GM, Chamness GC, Ulrrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
52. Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of HER/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992;118:474-9.
53. Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the HER-2/neu (c-erbB-2) gene. Chemotherapy 2001;47:297-303.
54. Huang S-M, Harai P. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary results. Invest New Drugs 1999;17:259-69.